Provectus circulated OneMedPlace Research's profile on the company.
As tends to be the case with buy-side (or pseudo buy-side, in the case of OMP) research, the material contain more declarative comments than their brethren and sistren on the sell-side (recall Dr. Jen's update in early December). It is a good read.
If you already have not received it directly from Provectus News (sign up, by the way), download it here.
No comments:
Post a Comment